Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Antiparkinsonian or Opioid or [[:Category:Tryptamines|Tryptamine]]

Use the filters below to narrow your results.

generic:
Codeine (2)
brand:
None (14) · (multiple, generic dominant) (1) · Akineton (1) · Alfenta (1) · Apokyn (1) · Artane (1) · Azilect (1) · Cogentin (1) · COMP360 (Compass Pathways, investigational synthesized clinical formulation) (1) · Comtan (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Dostinex (1) · Duragesic (1) · Eldepryl (1) · Heroin (1) · Krokodil (1) · Neupro (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Ongentys (1) · Opana (1) · Parlodel (1) · Sinemet (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Sufenta (1) · Symmetrel (1) · Talwin (1) · Tasmar (1) · Ultiva (1) · Vicodin (1) · Xadago (1)
classes: (Click arrow to add another value)
mechanism:
Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · Irreversible selective MAO-B inhibitor (2)
uses:
None (48) · (investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' (1) · Mild to moderate pain; cough suppression (low-dose). (1)
starting dose:
None (48) · Adult: 15–60 mg every 4 hours as needed. (1) · Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support (1)
preparations:
None (48) · Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (48) · 360 mg/day (1) · Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing (1)
routes:
None (48) · Oral (1) · PO (only formulation marketed in the US). (1)
onset:
None (48) · 20-45 min subjective onset; psilocin formation from psilocybin requires intestinal and hepatic alkaline phosphatase (1) · 30–60 min (PO) (1)
duration:
None (47) · 4-6 hours (1) · 4–6 hours (1) · About 20 minutes (1)
halflife:
None (47) · 2.5–3 hours (1) · 9–12 minutes (intravenous) (1) · Psilocin: ~2-3 h; psilocybin itself is a prodrug, dephosphorylated within minutes of absorption (1)
bioavailability:
None (48) · Oral bioavailability of psilocin from administered psilocybin approximately 50% (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (48) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Not studied in human pregnancy; no approved clinical use in any population (1)
legal:
None (48) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)

Showing below up to 50 results in range #1 to #50.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"